Noticias de PSTV_US

Noticias del mercado

Últimas noticias sobre PSTV_US — 160 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PSTV_US ✕ 160 resultados
21/04/2026 PSTV_US — MarketScreener ES ← EN
Plus Therapeutics vuelve a cumplir con el requisito de precio mínimo de oferta del Nasdaq

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

21/04/2026 PSTV_US — news.futunn.com ES ← EN
Plus Therapeutics vuelve a cumplir con el requisito de precio mínimo de oferta del Nasdaq

Plus Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

21/04/2026 PSTV_US — The Globe and Mail
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/04/2026 PSTV_US — GlobeNewswire ES ← EN
Plus Therapeutics vuelve a cumplir con el requisito de precio mínimo de oferta del Nasdaq

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

21/04/2026 PSTV_US — ChartMill
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/04/2026 PSTV_US — GuruFocus
Plus Therapeutics (PSTV) Meets Nasdaq Bid Price Requirement
21/04/2026 PSTV_US — TradingView
Plus Therapeutics regains Nasdaq compliance after one-for-25 reverse split
21/04/2026 PSTV_US — Stock Titan
Plus Therapeutics (NASDAQ: PSTV) back in line with Nasdaq bid rules
21/04/2026 PSTV_US — Stock Titan
Plus Therapeutics (PSTV) CDO reports no common stock ownership
21/04/2026 PSTV_US — Sahm
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/04/2026 PSTV_US — Stock Titan
Plus Therapeutics clears $1 bid test, Nasdaq closes matter
21/04/2026 PSTV_US — GlobeNewswire
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/04/2026 PSTV_US — Yahoo Finance
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
20/04/2026 PSTV_US — MSN ES ← EN
Plus Therapeutics obtiene el estatus de medicamento huérfano de la FDA para el tratamiento del glioma pediátrico
15/04/2026 PSTV_US — GlobeNewswire ES ← EN
Plus Therapeutics nombra a Randy H. Goodman, PhD, MHA, como
15/04/2026 PSTV_US — Stock Titan
Harvard-trained reimbursement expert joins Plus for CNS cancer push
15/04/2026 PSTV_US — Yahoo Finance
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
15/04/2026 PSTV_US — Investing.com
Plus Therapeutics appoints Randy Goodman to lead market access
15/04/2026 PSTV_US — citybiz
Plus Therapeutics Hires Randy Goodman to Lead Market Access and Value Strategy
15/04/2026 PSTV_US — GlobeNewswire
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as

Página 5 de 8

keyboard_arrow_up